Skip to content

Sotera Health Company

US · SHC #2097 by market cap Listed 2020
15.91 -0.30 -1.85%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:00

Recent news

  • Company notice
    PURPOSE INVESTMENTS INC. GLOBAL INNOVATORS FD ETF SHS: MATERIAL CHANGE REPORT EN
    SEDAR · 2026/11/10
  • ENBRIDGE INC 4% CUM RED PFD SHS SER D CAD25.00 To Go Ex-Dividend On November 13th, 2026 With 0.23843 USD Dividend Per Share
    Market Newswire · 2026/11/12
  • Rating change
    Jefferies Remains a Buy on Light & Wonder, Inc. Shs Chess Depository Interests Repr 1 Sh (LNW)
    TipRanks · 2026/10/22
  • EDREAMS ODIGEO UNSP ADR EACH REP 10 ORD SHS(EDEMY.US) will release its financial report on November 17.
    Market Newswire · 2026/11/13
  • WAFD INC DEP SHS REP 1/40TH PERP PFD SER A USD25. To Go Ex-Dividend On December 31st, 2026 With 0.30469 USD Dividend Per Share
    Market Newswire · 2026/11/12
  • Company notice
    PURPOSE INVESTMENTS INC. GLOBAL INNOVATORS FD ETF SHS: MATERIAL CHANGE REPORT FR
    SEDAR · 2026/11/10
  • Rating change
    RBC Capital Maintains Sotera Health Company(SHC.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/11/4
  • Rating change
    Erste Group Downgrades SCHNEIDER ELECTRIC SE UNSPON ADR EA REPR 0.20 ORD SHS(SBGSY.US) to Hold Rating
    Market Newswire · 2026/10/21
  • Rating change
    UBS Keeps Their Buy Rating on Southern Cross Gold Consolidated Ltd. Chees Depository Interest Repr 1 Shs (SX2)
    TipRanks · 2026/10/20
  • Company notice
    GRUPO TMM S.A.B. SPON ADR EACH REP 5 SER A SHS | 6-K: Report of foreign private issuer (related to financial reporting)
    SEC · 2026/11/4
  • Rating change
    Ord Minnett Keeps Their Buy Rating on NexGen Energy Ltd. Shs Chess Depository Interests Repr 1 Shs (NXG)
    TipRanks · 2026/10/20
  • Company notice
    PURPOSE INVESTMENTS INC. GLOBAL INNOVATORS FD ETF SHS: NEWS RELEASE FR
    SEDAR · 2026/11/7
  • Rating change
    Piper Sandler Maintains Sotera Health Company(SHC.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/10/19
  • ENBRIDGE INC CUM RED PRF SHS B CAD25.00 To Go Ex-Dividend On November 13th, 2026 With 0.22918 USD Dividend Per Share
    Market Newswire · 2026/11/12
  • Rating change
    J.P. Morgan Maintains Sotera Health Company(SHC.US) With Sell Rating, Cuts Target Price to $15
    Market Newswire · 2026/11/4
  • ENBRIDGE INC 4% CUM RED PRF SHS SER 'L' USD25.00 To Go Ex-Dividend On November 13th, 2026 With 0.36612 USD Dividend Per Share
    Market Newswire · 2026/11/12
  • Rating change
    Citi Remains a Buy on Light & Wonder, Inc. Shs Chess Depository Interests Repr 1 Sh (LNW)
    TipRanks · 2026/10/23
  • Rating change
    Barclays Maintains Sotera Health Company(SHC.US) With Buy Rating, Cuts Target Price to $20
    Market Newswire · 2026/11/4
  • Company notice
    PURPOSE INVESTMENTS INC. GLOBAL INNOVATORS FD ETF SHS: NEWS RELEASE EN
    SEDAR · 2026/11/7
  • Rating change
    BMO Capital Maintains Sotera Health Company(SHC.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/11/5
  • BANCO BPM SPA UNSPON ADR EACH REPR 4 ORD SHS(BNNCY.US) is scheduled to release its financial report before the market opens on November 5.
    Market Newswire · 2026/10/31
  • NEMETSCHEK SE UNSPON ADS EACH REP 0.2 ORD SHS (NEMKY.US) will release its financial report before the market opens on November 5.
    Market Newswire · 2026/10/31
  • FINECOBANK SPA UNSP ADR EACH REP 2 ORD SHS(FNBKY.US) will release its financial report on November 5.
    Market Newswire · 2026/10/30
  • Company notice
    PURPOSE INVESTMENTS INC. PREM YIELD FD ETF SHS: INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE FR
    SEDAR · 2026/10/16
  • Rating change
    J.P. Morgan Maintains Sotera Health Company(SHC.US) With Sell Rating, Maintains Target Price $17
    Market Newswire · 2026/10/14

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 16:00:57 · For reference only, not investment advice and not tailored to your situation.

Sotera Health Company discussion 0 comments

Add a comment